Regado Launches Phase III Trial Testing First-in-Class Clotbuster
By Catherine Shaffer
Tuesday, September 17, 2013
Regado Biosciences Inc., of Basking Ridge, N.J., enrolled its first patient in the Phase III REGULATE-PCI trial of its antithrombotic drug, REG1, in patients undergoing percutaneous coronary intervention (PCI). The trial will compare REG1 to Angiomax (bivalirudin, The Medicines Co.).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.